396
Participants
Start Date
March 12, 2009
Primary Completion Date
August 19, 2019
Study Completion Date
August 19, 2019
Riociguat (BAY63-2521)
BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
Taipei
Bruxelles - Brussel
Vienna
Darlinghurst
Leuven
Prahran
Linz
Herston
Auchenflower
Innsbruck
Hobart
Zurich
Aarhus N
Bangkok
Taipei
Prague
Mexico City
Greifswald
Milan
Besançon
Pavia
Hanover
Pessac
Montpellier
Istanbul
Trieste
Giessen
Querétaro
Grenoble
Columbus
Cleveland
"Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde", Guadalajara
Pulmocritic, Guadalajara
Fairfield
Chiang Mai
Cologne
Lille
Monterrey
Homburg
Omaha
Heidelberg
Rouen
El Paso
Culiacán
Aurora
München
Los Angeles
Sacramento
Beijing
Beijing
Singapore
Moscow
Singapore
Saint Petersburg
Shanghai
Shanghai
Guangzhou
Kaohsiung City
Boston
Boston
Dallas
Capital Federal
Ankara
Porto Alegre
São Paulo
São Paulo
Rio de Janeiro
Calgary
Montreal
Brest
Dresden
Leipzig
Chaïdári
Rome
Nagoya
Kobe
Toride
Tsukuba
Kanazawa
Sendai
Tomigusuku
Bunkyo-ku
Mitaka
Ōta-ku
Shinjuku-ku
Hiroshima
Okayama
Otwock
Coimbra
Lisbon
Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisbon
Seoul
Seoul
Seoul
Umeå
Izmir
Cambridge
Clydebank
London
Lead Sponsor
Bayer
INDUSTRY